The multi-omics and Mendelian randomization analyses unveiled potential marker genes in the progression of glioblastoma

多组学和孟德尔随机化分析揭示了胶质母细胞瘤进展中的潜在标志基因

阅读:1

Abstract

In glioma research, identifying key molecules for predicting patient prognosis is challenging due to high heterogeneity. This study explores the correlation between alternative splicing (AS) and glioma prognosis, aiming to identify molecular markers for potential treatments. Retrieve transcriptomic and clinical data of glioma samples from the cancer genome atlas, eQTLGen database, and GWAS Catalog database. Build a predictive model for patient prognosis using the lasso-cox method. Machine learning is employed to identify the most diagnostically and predictively valuable biomarkers or features. Mendelian randomization analysis is employed to evaluate the causal relationship between genes and diseases. gene ontology, Kyoto encyclopedia of genes and genomes are utilized to explore the potential pathways and mechanisms of genes. The lasso algorithm was employed to screen various AS-related genes across different types, resulting in distinct gene sets. Subsequently, predictive models for patient prognosis were constructed. Key genes, including "STEAP3," "MLC1," "ARHGAP19," "LFNG," "NRG1" and "KLC1" were identified through lasso screening. Mendelian randomization analysis highlighted the significance of NRG1 in glioma development. gene ontology analysis, encompassing biological processes, cellular components, and molecular functions, revealed enrichment in processes such as modulation of chemical synaptic transmission and ion channel activity. Moreover, Kyoto encyclopedia of genes and genomes pathways, such as Calcium signaling, MAPK signaling, cAMP signaling, and Rap1 signaling, were significantly enriched. In conclusion, our model, based on AS genes, effectively predicts glioma prognosis, identifying NRG1 as a significant marker.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。